drugset / Trial / NCT00020540
Biological Therapy in Treating Patients With Metastatic Melanoma or Metastatic Kidney Cancer
Treatment
Summary
RATIONALE: Biological therapies such as flt3L and CD40-ligand use different ways to stimulate the immune system and stop cancer cells from growing. Biological therapy may be an effective treatment for metastatic melanoma and metastatic kidney cancer. PURPOSE: Phase I trial to study the effectiveness of flt3L combined with CD40-ligand in treating patients who have metastatic melanoma or metastatic kidney cancer.
Timeline
- Start
- 2001-03
- Primary completion
- —
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CD40-ligand | Protein / enzyme biologic | — | Subcutaneous |
| Background | flt3 ligand | Protein / enzyme biologic | — | Subcutaneous |